HomeAbout UsContact Us
Home

 

Accreditation Statement: This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc.  The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.  The Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for physicians.

The Mount Sinai School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty Disclosure Policy Statement: It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices.

Target Audience  This activity will benefit psychiatrists, hospital staff physicians, and office-based “attending” physicians from the community.

To obtain credit you should score 70% or better.  The estimated time to complete this activity is 1 hour.




TitleSummary
Schizophrenia and Bipolar Disorder--Part 3: Recent Advances in the Treatment of Bipolar Disorder     This is the final installment of a three-part series covering recent advances in diagnosis and treatment of schizophrenia and bipolar disorder. This third feature focuses on the development of new treatment strategies for bipolar disorder, their implications for existing treatments, and the importance of acute clinical investigation of their outcomes.
Schizophrenia and Bipolar Disorder - Pt. 2: Recent Advances in the Treatment of Schizophrenia     This is the second of a three-part CME series covering recent advances in diagnosis and treatment of schizophrenia and bipolar disorder. This second feature focuses on the development of new treatment strategies for schizophrenia and the importance of acute clinical investigation of their outcomes.
Schizophrenia and Bipolar Disorder - Part 1: Etiology and Diagnosis     This is the first of a three-part CME series covering recent advances in diagnosis and treatment of schizophrenia and bipolar disorder.
Free CME: Special Considerations in Diagnosing and Treating ADHD: Part 3: Adults     This is the final poster in a 3-part Psychiatry Weekly CME series on special considerations in diagnosing and treating ADHD. Part 1 focused on the preschool-age population, and part 2 covered children and adolescents.
Free Online CME: Diagnosing and Treating ADHD: Part 2: Children and Adolescents     This is the second in a 3-part Psychiatry Weekly CME series on special considerations in diagnosing and treating ADHD. Part 1 focused on the preschool-age population, and part 3 will focus on the adult population.
Free Online CME: Special Considerations in Diagnosing and Treating ADHD Part 1: Preschool-Age Children     New evidence highlights the need to refine the strategies employed by clinicians in diagnosing and treating preschool-age children with ADHD.
Free Online CME: Diagnosis and Management Considerations in Acute and Maintenance Treatment of Schizophrenia     Schizophrenia is among the world’s top 10 causes of long-term disability, affecting ~1% of the United States population, with similar rates across countries, cultural groups, and genders.